MetaCap

C4 Therapeutics (CCCC) vs Precision BioSciences (DTIL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Precision BioSciences (DTIL) has outperformed C4 Therapeutics (CCCC) over the past year, gaining 48.0% versus a gain of 1.6%. Over five years, CCCC leads with a -93.2% price change compared with -97.2% for DTIL. C4 Therapeutics is the larger company by market cap ($325.7 million vs $282.5 million), about 1.2 times the size.

Precision BioSciences converts more of its revenue into profit, with a net margin of -133.4% versus -292.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CCCC+1.64%DTIL+48.00%
+119%+41%-37%
Nov 21, 20251 yearNov 20, 2026
CCCC-93.55%DTIL-97.36%
+5%-49%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CCCC versus DTIL key metrics
MetricCCCCDTIL
Share price$2.48$7.40
Market cap$325.67M$282.46M
1-day change+1.64%+7.09%
YTD return+29.84%+77.88%
1-year return+1.64%+48.00%
5-year return-93.23%-97.23%
P/E ratio (TTM)—29.60
EPS (TTM)$-0.63$0.25
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$35.95M$34.26M
Revenue growth (YoY)+1.02%-50.12%
Net income (latest FY)$-104.99M$-45.72M
Operating margin-320.53%-152.19%
Net margin-292.08%-133.45%
52-week high$5.17$11.29
52-week low$1.69$3.53
Distance from 52-week high-52.03%-34.46%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+404.03%+297.30%
Average volume2.57M319.79K
Shares outstanding131.32M38.17M
Employees10469
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DTIL has outperformed CCCC by 46.4 percentage points over the past year.
  • Precision BioSciences is more profitable, keeping -133.4 cents of every revenue dollar as net income versus -292.1 cents for C4 Therapeutics.
  • C4 Therapeutics grew revenue faster in its latest fiscal year (+1.02% vs -50.12%).

About C4 Therapeutics

CCCC stock →

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees

About Precision BioSciences

DTIL stock →

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 69 employees

CCCC vs DTIL FAQ

Which is bigger, C4 Therapeutics or Precision BioSciences?

C4 Therapeutics (CCCC) is larger, with a market capitalization of $325.67M compared with $282.46M for Precision BioSciences (DTIL).

Which stock has performed better over the past year, CCCC or DTIL?

DTIL returned +48.00% over the past 12 months, compared with +1.64% for CCCC (price return, excluding dividends). Past performance does not predict future results.

Are C4 Therapeutics and Precision BioSciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons